search
Back to results

RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

Primary Purpose

Systemic Sclerosis

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
RIC alloBMT w PTCy in refractory SSc
Sponsored by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Systemic Sclerosis

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Recipient Inclusion Criteria:

All patients with moderate-to-severe SSc will be considered for this trial, including women and minorities. SSc is too rare a disease in children for it to be feasible to include them.

Patients must meet the following criteria to be eligible for participation in this clinical trial:

  1. 2013 ACR/EULAR Criteria for Systemic Sclerosis
  2. Active diffuse cutaneous disease with an mRSS ≥ 20 - including increasing skin score, new body areas involved, increased thickening in previously affected body areas, severe pruritus, tendon friction rubs OR concern for active interstitial lung disease (ILD) with FVC<70% of predicted, new fibrosis/GGO on HRCT, and/or falling FVC >10% of predicted
  3. Lack of response to first line therapy including mycophenolate mofetil at maximum tolerated dose (up to 1.5 grams BID) after 10 weeks and/or equivalent degree of immunosuppression/immunomodulatory therapy with MTX, CYC, IVIG, or rituximab. Lack of response can include physician judgement based on review of records and patient report.
  4. Age >18 years and ≤ 65 years
  5. Patients should be eligible for transplantation according to the BMT Policy Manual.
  6. Female patients (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months post-transplant. Effective birth control is defined as the following:

    • Abstinence
    • Consistently use birth control pills or patch
    • Use injectable birth control (for example, Depo-Provera or Norplant)
    • Have tubal sterilization
    • Have placement of an IUD
  7. Use of a diaphragm with contraceptive jelly and/or condoms with contraceptive foam every time you have vaginal sex. Male patients (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant. Effective birth control methods include:

    • Abstinence
    • Vasectomy or female partner who had a tubal ligation
    • Use of condoms with contraceptive foam
  8. Adequate organ function defined as:

    1. Cardiac: Left ventricular ejection fraction (LVEF) at rest ≥ 45%. Systolic BP between 90- 170 mmHg Pulse between 60 and 100 bpm Respiratory Rate between 10 and 25 breaths per minute O2 saturation >92% on Room Air
    2. Hepatic: Total bilirubin < 3.0 x the upper limit of normal (ULN) (patients who have been diagnosed with Gilbert's Disease are allowed to exceed this limit) and AST and ALT < 2.0 x ULN.
    3. Renal: estimated creatinine clearance ≥ 40 mL/minute (using the Cockcroft-Gault formula and actual body weight).

      Cockcroft-Gault formula, based on ideal body weight (IBW):

      CrCl = (140 - age) x IBW (kg) x 0.85 for females/ PCr x 72

    4. Pulmonary: DLCO (corrected/adjusted for hemoglobin) > 50% and FEV1 > 50% predicted (without administration of bronchodilator) and FVC > 60% predicted.
  9. Karnofsky performance score>70%

Donor inclusion criteria:

  1. HLA-matched or -haploidentical, parent, child, sibling, or half-sibling of the recipient
  2. Eligible as per donor selection in FDA 21 CFR Part 1271
  3. Meets all requirements for bone marrow donor selection criteria as described in the standard Johns Hopkins BMT Policies and Procedures.
  4. Medically healthy with no clinically significant findings in the physical examination, medical history, vital signs
  5. No history of any clinically significant immunosuppressive or autoimmune disease including hematologic malignancy or history of solid organ or allogeneic bone marrow transplantation;
  6. Ability to understand and provide informed consent for all study procedures including bone marrow harvest.

Recipient Exclusion Criteria:

  1. Pregnant, breast feeding or considering becoming pregnant.
  2. Patients who are pre-terminal or moribund.
  3. Administration of an investigational compound either currently or within 30 days of beginning treatment;
  4. History of or positive serologic test for HIV, hepatitis B or C by PCR ; or any potentially communicable infectious disease as determined by the Investigator
  5. History of or positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response or evidence of viral clearance without prior treatment);
  6. Current or history of clinically significant diseases except for known scleroderma, including gastrointestinal, renal, hepatic, neurologic (e.g., epilepsy, neuropathy), hematologic, endocrine (e.g., diabetes), oncologic, pulmonary, immunologic, psychiatric, or any other condition, which, in the judgment of the investigator, is considered uncontrolled and would jeopardize the safety of the subject, interfere with study assessments or impact the validity of the study results.
  7. Known malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  8. Know additional abnormality suggestive of a disease and/or organ toxicity other than systemic sclerosis
  9. Uncontrolled diabetes with an HbA1C of >8%
  10. Acute kidney injury within the last 6 weeks/months
  11. Prior major surgery or radiation therapy within 4 weeks of beginning treatment;

    a. Administration of any live vaccine within 4 weeks of beginning treatment; Does not exclude COVID-19 vaccine

  12. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, or low-dose methotrexate). Systemic corticosteroids must be discontinued at least 4 weeks prior to beginning treatment;
  13. Prisoner or subjects who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness;
  14. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints;
  15. History of allergic reactions, hypersensitivity, or intolerance attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study.
  16. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  17. Myocardial infarction (MI) within 6 months prior to study entry, New York Heart Association (NYHA) Class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
  18. Either of the following:

    1. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) is <45% of predicted normal. Note that FEV1 testing also is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is <50% of predicted normal.
    2. Known moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification. (Subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study.)
  19. Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint.
  20. Any subject who meets the following European Society for Blood and Marrow

    Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) cardiopulmonary criteria should be excluded from high dose cyclophosphamide containing HSCT regimens:

    • Evidence of pulmonary arterial hypertension including baseline (resting) PASP > 40 mmHg or mPAP > 25 mmHg or PASP > 45 mmHg or mPAP > 30 mmHg after fluid challenge
    • LVEF < 45% x Cardiographic signs of right ventricular dysfunction such as diastolic septal flattening (D-sign)
    • Constrictive pericarditis or cardiac tamponade
    • Significant atherosclerotic disease
    • Severe untreated arrhythmias
  21. Severe ILD defined by the following:

    • FVC < 60% at either screening or baseline.
    • DLCO Hb <50% at either screening or baseline

Sites / Locations

  • Johns Hopkins UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

RIC- alloBMT with high PTCy in SSc

Arm Description

Days -9 Thymoglobulin 0.5 mg/kg IV Days -8,-7 Thymoglobulin 2 mg/kg IV daily Days -6, -5 Fludarabine 30 mg/M2 IV Cyclophosphamide 14.5 mg/kg IV Days -4, -3-2 Fludarabine 30 mg/M2 IV Day -1 TBI 400 cGy Day 0 Infuse unmanipulated marrow; begin antimicrobial prophylaxis. Days 3, 4 Cy 50 mg/kg IV and Mesna 40 mg/kg IV Day 5 FK-506 oral and MMF oral and G-CSF Day 30 Assess peripheral blood chimerism Day 35 Discontinue MMF Day 60 Assess peripheral blood chimerism Day 180 Discontinue FK-506 Evaluate disease Assess Chimerism in peripheral blood 1 yr. Evaluate disease by peripheral blood chimerism

Outcomes

Primary Outcome Measures

Acute Graft vs Host disease (GVHD) incidence
Number of safety events defined as CTCAE grade III-IV acute GVHD.
Chronic Graft vs Host disease (GVHD) incidence
Number of participants with chronic GVHD requiring systemic immune suppression.
Disease relapse or progression incidence
Number of participants diagnosed with disease relapse or progression.
Incidence of death
Number of participant deaths by any cause.

Secondary Outcome Measures

Event free survival- pulmonary hypertension
Number of participants with a new diagnosis of pulmonary hypertension by right heart cardiac catheterization (mean PAP>25 mmHg).
Event free survival- cardiomyopathy
Number of participants with a new diagnosis of cardiomyopathy (Left ventricular function <30% on ECHO).
Event free survival- increased mRSS scoring in diffuse scleroderma patients
Number of participants initially diagnosed with diffuse scleroderma with an increase in mRSS score by 5 points.
Event free survival- renal crisis
Number of participants with new renal crisis.
Event free survival- pulmonary function assessment
Number of participant who experience a 10% or greater decrease in forced vital capacity (FVC) OR a 5-10% decrease in FVC AND 15% or greater decrease in diffusing capacity of the lungs for carbon monoxide (DLCO).
Event free survival- CTCAE v5 Grade 3 or higher toxicities
Number of grade 3 or higher toxicity events based on CTCAE v5.
Event free survival- incidence of serious infections
Number of grade 3 or higher infections based on CTCAE v5 criteria.
Event free survival- increased rate of revised Minnesota high risk aGVHD
Number participants with increased high risk aGVHD according to revised Minnesota high risk aGVHD criteria.
Event free survival- proportion off immunosuppression without GVHD or disease recurrence
Proportion of participants who are off of immunosuppression without GVHD or disease recurrence at 12 months post transplantation.
Event free survival- hematologic recovery
Number of participants who have experienced hematologic recovery at 12 months based on neutrophil and platelet counts.
Event free survival- donor cell engraftment
Number of participants who experience donor cell engraftment based on chimerism reports.
Event free survival- transplant related death
Number of participant who die and whose death are attributed to transplant.

Full Information

First Posted
March 7, 2022
Last Updated
January 9, 2023
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
search

1. Study Identification

Unique Protocol Identification Number
NCT05298358
Brief Title
RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis
Official Title
A Phase I Study of Reduced Intensity Conditioning Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 18, 2022 (Actual)
Primary Completion Date
August 15, 2027 (Anticipated)
Study Completion Date
November 15, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase I, single arm, open label, single center pilot study to assess a reduced-intensity conditioning regimen, bone marrow transplantation with high dose cyclophosphamide (PTCy) in recipients with refractory systemic sclerosis. This study expects to enroll 15 donor/recipient pairs for a total of 30 participants. The primary objective of this study is to assess the safety of using a reduced intensity condition (RIC) preparative regimen bone marrow transplant (BMT) with post-transplant cyclophosphamide for graft vs host disease (GVHD) prophylaxis as treatment for patients with scleroderma. Safety events are grade III-IV GVHD and treatment related mortality within 1 year. Eligibility includes patients >18 years who are eligible for transplantation according to the BMT Policy Manual, meet the 2013 ACR/EULAR Criteria for Systemic Sclerosis and display active diffuse cutaneous disease. The trial also includes analyses of the effects of BMT on skeletal and cardiac muscle using systemic scleroderma serum biomarkers of CK, aldolase, and troponin as well as periodic monitoring of circulating scleroderma auto-antibody titers, autoreactive T cells, and flow cytometric signatures over the one-year study period to correlate with response.
Detailed Description
The purpose of this study is to find out if the drug cyclophosphamide given after bone marrow transplantation is safe and effective in patients with systemic sclerosis that have not responded to other standard treatments. Systemic sclerosis (scleroderma) is a systemic autoimmune disease associated with high morbidity and mortality, with an estimated prevalence of 50-300 per million persons/year and incidence of 2.3-22.9 per million persons/year. Currently there exists no cure for scleroderma, and medical management is entirely off-label, with no FDA approved drugs for this condition. Treatment is based on symptom management focused on the specific organ system affected such as the lung, skin, musculoskeletal, cardiac, renal, or gastrointestinal systems. Interest in improving response rates and decreasing relapse has turned attention toward allogeneic stem cell transplantation (allo-BMT). The possibility of maintaining control of autoimmunity by means of mixed chimerism in these autoimmune diseases is quite important. These patients may not need full engraftment to have disease modification. There is still concern about the morbidity GVHD for these patients in the allogeneic setting as well as a potentially limited number of available donors. Towards this end, the study was developed with an approach to BMT using post-transplant cyclophosphamide (PTCy) that allows safe performance of allogeneic BMT from matched, mismatched, unrelated or haploidentical donors. Given that there are responses of refractory systemic sclerosis (SSc) to immunosuppressive therapy in some form, eligible patients will be required to have experienced disease progression despite at least one course of immunosuppressive therapy. In general, this will be defined as progression of skin or lung disease despite optimal courses of therapy or failure to tolerate therapeutic doses of immunosuppressive therapy. Potential donors will be excluded if the donors report a history of autoimmunity. The rationale for this comes from the knowledge that gender, a genetically controlled factor, plays a role in the incidence of autoimmune disease. The study regimen includes several days of chemotherapy, immunosuppressant, and a single dose of radiation followed by the bone marrow transplant. After the transplant, recipient patients will receive two doses of the intravenous (IV, through a vein) chemotherapy cyclophosphamide and two oral medications to prevent graft versus host disease and to aid in bone marrow engraftment. After a while, the anti-rejection medications are stopped. During this time, a chimerism assay that defines how much of the blood comes from donor cells and how much of the blood comes from the recipient will be performed at four weeks, eight weeks, six months, one year after the transplant. This test will tell if the donor's transplanted cells are surviving long term in the recipient. If a recipient participant is eligible, the study regimen will begin about 30 days before bone marrow transplantation and participation will continue for up to 1 year after transplant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Sclerosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RIC- alloBMT with high PTCy in SSc
Arm Type
Experimental
Arm Description
Days -9 Thymoglobulin 0.5 mg/kg IV Days -8,-7 Thymoglobulin 2 mg/kg IV daily Days -6, -5 Fludarabine 30 mg/M2 IV Cyclophosphamide 14.5 mg/kg IV Days -4, -3-2 Fludarabine 30 mg/M2 IV Day -1 TBI 400 cGy Day 0 Infuse unmanipulated marrow; begin antimicrobial prophylaxis. Days 3, 4 Cy 50 mg/kg IV and Mesna 40 mg/kg IV Day 5 FK-506 oral and MMF oral and G-CSF Day 30 Assess peripheral blood chimerism Day 35 Discontinue MMF Day 60 Assess peripheral blood chimerism Day 180 Discontinue FK-506 Evaluate disease Assess Chimerism in peripheral blood 1 yr. Evaluate disease by peripheral blood chimerism
Intervention Type
Biological
Intervention Name(s)
RIC alloBMT w PTCy in refractory SSc
Intervention Description
The preparative regimen: Thymoglobulin 0.5 mg/kg IV day -9 Thymoglobulin 2 mg/kg IV Days -8, -7 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5 Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2 Total body irradiation (TBI) 400cGy Day 0- infusion of unmanipulated bone marrow The GVHD prophylaxis regimen: Cy 50 mg/kg IV Days 3, 4 Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus. Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35 Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days. Supportive care: Mesna- 10 mg/kg/ IV Day 3, 4 Patients will receive infection prophylaxis and treatment according to institutional guidelines.
Primary Outcome Measure Information:
Title
Acute Graft vs Host disease (GVHD) incidence
Description
Number of safety events defined as CTCAE grade III-IV acute GVHD.
Time Frame
1 year
Title
Chronic Graft vs Host disease (GVHD) incidence
Description
Number of participants with chronic GVHD requiring systemic immune suppression.
Time Frame
1 year
Title
Disease relapse or progression incidence
Description
Number of participants diagnosed with disease relapse or progression.
Time Frame
1 year
Title
Incidence of death
Description
Number of participant deaths by any cause.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Event free survival- pulmonary hypertension
Description
Number of participants with a new diagnosis of pulmonary hypertension by right heart cardiac catheterization (mean PAP>25 mmHg).
Time Frame
1 year
Title
Event free survival- cardiomyopathy
Description
Number of participants with a new diagnosis of cardiomyopathy (Left ventricular function <30% on ECHO).
Time Frame
1 year
Title
Event free survival- increased mRSS scoring in diffuse scleroderma patients
Description
Number of participants initially diagnosed with diffuse scleroderma with an increase in mRSS score by 5 points.
Time Frame
1 year
Title
Event free survival- renal crisis
Description
Number of participants with new renal crisis.
Time Frame
1 year
Title
Event free survival- pulmonary function assessment
Description
Number of participant who experience a 10% or greater decrease in forced vital capacity (FVC) OR a 5-10% decrease in FVC AND 15% or greater decrease in diffusing capacity of the lungs for carbon monoxide (DLCO).
Time Frame
1 year
Title
Event free survival- CTCAE v5 Grade 3 or higher toxicities
Description
Number of grade 3 or higher toxicity events based on CTCAE v5.
Time Frame
1 year
Title
Event free survival- incidence of serious infections
Description
Number of grade 3 or higher infections based on CTCAE v5 criteria.
Time Frame
1 year
Title
Event free survival- increased rate of revised Minnesota high risk aGVHD
Description
Number participants with increased high risk aGVHD according to revised Minnesota high risk aGVHD criteria.
Time Frame
1 year
Title
Event free survival- proportion off immunosuppression without GVHD or disease recurrence
Description
Proportion of participants who are off of immunosuppression without GVHD or disease recurrence at 12 months post transplantation.
Time Frame
1 year
Title
Event free survival- hematologic recovery
Description
Number of participants who have experienced hematologic recovery at 12 months based on neutrophil and platelet counts.
Time Frame
1 year
Title
Event free survival- donor cell engraftment
Description
Number of participants who experience donor cell engraftment based on chimerism reports.
Time Frame
1 year
Title
Event free survival- transplant related death
Description
Number of participant who die and whose death are attributed to transplant.
Time Frame
1 year
Other Pre-specified Outcome Measures:
Title
Additional exploratory objective- serum CK
Description
To assess the effects of BMT on skeletal and cardiac muscle
Time Frame
1 year
Title
Additional exploratory objective- serum aldolase
Description
To assess the effects of BMT on skeletal and cardiac muscle
Time Frame
1 year
Title
Additional exploratory objective- serum troponin
Description
To assess the effects of BMT on skeletal and cardiac muscle
Time Frame
1 year
Title
Additional exploratory objective- scleroderma autoantibody titers
Description
Assess impact of BMT on histologic scleroderma biomarkers by measuring amount of autoantibodies
Time Frame
1 year
Title
Additional exploratory objective- autoreactive T cells
Description
Assess impact of BMT on histologic scleroderma biomarkers by measuring amount of autoreactive T cells
Time Frame
1 year
Title
Additional exploratory objective- flow cytometric analysis of HLA-A, B or DR biomarkers on lymphocytes
Description
Assess impact of BMT on histologic scleroderma biomarkers by assessment of flow cytometry. Complete donor chimerism will be defined as >95%.Mixed donor chimerism will be defined as >5%, but <95% CD3+ cells of donor origin.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Recipient Inclusion Criteria: All patients with moderate-to-severe SSc will be considered for this trial, including women and minorities. SSc is too rare a disease in children for it to be feasible to include them. Patients must meet the following criteria to be eligible for participation in this clinical trial: 2013 ACR/EULAR Criteria for Systemic Sclerosis Active diffuse cutaneous disease with an mRSS ≥ 20 - including increasing skin score, new body areas involved, increased thickening in previously affected body areas, severe pruritus, tendon friction rubs OR concern for active interstitial lung disease (ILD) with FVC<70% of predicted, new fibrosis/GGO on HRCT, and/or falling FVC >10% of predicted Lack of response to first line therapy including mycophenolate mofetil at maximum tolerated dose (up to 1.5 grams BID) after 10 weeks and/or equivalent degree of immunosuppression/immunomodulatory therapy with MTX, CYC, IVIG, or rituximab. Lack of response can include physician judgement based on review of records and patient report. Age >18 years and ≤ 65 years Patients should be eligible for transplantation according to the BMT Policy Manual. Female patients (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months post-transplant. Effective birth control is defined as the following: Abstinence Consistently use birth control pills or patch Use injectable birth control (for example, Depo-Provera or Norplant) Have tubal sterilization Have placement of an IUD Use of a diaphragm with contraceptive jelly and/or condoms with contraceptive foam every time you have vaginal sex. Male patients (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post-transplant. Effective birth control methods include: Abstinence Vasectomy or female partner who had a tubal ligation Use of condoms with contraceptive foam Adequate organ function defined as: Cardiac: Left ventricular ejection fraction (LVEF) at rest ≥ 45%. Systolic BP between 90- 170 mmHg Pulse between 60 and 100 bpm Respiratory Rate between 10 and 25 breaths per minute O2 saturation >92% on Room Air Hepatic: Total bilirubin < 3.0 x the upper limit of normal (ULN) (patients who have been diagnosed with Gilbert's Disease are allowed to exceed this limit) and AST and ALT < 2.0 x ULN. Renal: estimated creatinine clearance ≥ 40 mL/minute (using the Cockcroft-Gault formula and actual body weight). Cockcroft-Gault formula, based on ideal body weight (IBW): CrCl = (140 - age) x IBW (kg) x 0.85 for females/ PCr x 72 Pulmonary: DLCO (corrected/adjusted for hemoglobin) > 50% and FEV1 > 50% predicted (without administration of bronchodilator) and FVC > 60% predicted. Karnofsky performance score>70% Donor inclusion criteria: HLA-matched or -haploidentical, parent, child, sibling, or half-sibling of the recipient Eligible as per donor selection in FDA 21 CFR Part 1271 Meets all requirements for bone marrow donor selection criteria as described in the standard Johns Hopkins BMT Policies and Procedures. Medically healthy with no clinically significant findings in the physical examination, medical history, vital signs No history of any clinically significant immunosuppressive or autoimmune disease including hematologic malignancy or history of solid organ or allogeneic bone marrow transplantation; Ability to understand and provide informed consent for all study procedures including bone marrow harvest. Recipient Exclusion Criteria: Pregnant, breast feeding or considering becoming pregnant. Patients who are pre-terminal or moribund. Administration of an investigational compound either currently or within 30 days of beginning treatment; History of or positive serologic test for HIV, hepatitis B or C by PCR ; or any potentially communicable infectious disease as determined by the Investigator History of or positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response or evidence of viral clearance without prior treatment); Current or history of clinically significant diseases except for known scleroderma, including gastrointestinal, renal, hepatic, neurologic (e.g., epilepsy, neuropathy), hematologic, endocrine (e.g., diabetes), oncologic, pulmonary, immunologic, psychiatric, or any other condition, which, in the judgment of the investigator, is considered uncontrolled and would jeopardize the safety of the subject, interfere with study assessments or impact the validity of the study results. Known malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. Know additional abnormality suggestive of a disease and/or organ toxicity other than systemic sclerosis Uncontrolled diabetes with an HbA1C of >8% Acute kidney injury within the last 6 weeks/months Prior major surgery or radiation therapy within 4 weeks of beginning treatment; a. Administration of any live vaccine within 4 weeks of beginning treatment; Does not exclude COVID-19 vaccine Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, or low-dose methotrexate). Systemic corticosteroids must be discontinued at least 4 weeks prior to beginning treatment; Prisoner or subjects who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness; Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; History of allergic reactions, hypersensitivity, or intolerance attributed to compounds of similar chemical or biologic composition to cyclophosphamide or other agents used in the study. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Myocardial infarction (MI) within 6 months prior to study entry, New York Heart Association (NYHA) Class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities. Either of the following: Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) is <45% of predicted normal. Note that FEV1 testing also is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is <50% of predicted normal. Known moderate or severe persistent asthma, or a history of asthma within the last 2 years, or currently has uncontrolled asthma of any classification. (Subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed to participate in the study.) Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint. Any subject who meets the following European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) cardiopulmonary criteria should be excluded from high dose cyclophosphamide containing HSCT regimens: Evidence of pulmonary arterial hypertension including baseline (resting) PASP > 40 mmHg or mPAP > 25 mmHg or PASP > 45 mmHg or mPAP > 30 mmHg after fluid challenge LVEF < 45% x Cardiographic signs of right ventricular dysfunction such as diastolic septal flattening (D-sign) Constrictive pericarditis or cardiac tamponade Significant atherosclerotic disease Severe untreated arrhythmias Severe ILD defined by the following: FVC < 60% at either screening or baseline. DLCO Hb <50% at either screening or baseline
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cole Sterling, MD
Phone
410-955-8893
Email
csterli4@jhmi.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Ackley, RN
Phone
410-502-0969
Email
lackley1@jhmi.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cole Sterling, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cole Sterling, MD
Phone
410-955-8893
Email
csterli4@jhmi.edu
First Name & Middle Initial & Last Name & Degree
Laura Ackley, RN
Phone
410-502-0969
Email
lackley1@jhmi.edu
First Name & Middle Initial & Last Name & Degree
Christopher Mecoli, MD

12. IPD Sharing Statement

Learn more about this trial

RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

We'll reach out to this number within 24 hrs